Objective To observe the clinical efficacy of Qingfei Huatan Decoction combined with moxifloxacin in the treatment of exterior cold and interior heat type of community-acquired pneumonia（ CAP）. Methods This study was an exploratory,prospective randomized controlled trial in which 70 patients with cold and interior heat type of community-acquired pneumonia were randomized into a trial group and a control group with 35 patients in each group. The control group was treated with intravenous infusion of moxifloxacin injection. The experimental group was given 200 m L of Qingfei Huatan Decoction on the basis of the control group 3 times a day. Both groups were treated for 7 days. The heat withdrawal time, cough VAS score before and after treatment,the blood routine,C-reactive protein,procalcitonin level,overall efficacy and safety evaluation were compared between the two groups. Results The antipyretic time of the experimental group（ 1. 34 ± 0. 93 days） was significantly shorter than that of the control group（ 2. 91 ± 1. 17 days）（ P < 0. 05）. The cough VAS scores of the two groups were significantly lowered than those before treatment（ P < 0. 05）. The experimental group was more obvious（ P < 0. 05）. The levels of WBC,CRP and PCT in both two groups were significantly lowered than those before treatment. The CRP in the experimental group was more significantly lowered than that in the control group（ P < 0. 05）. The total effective rate of the experimental group was 93. 94 %, and that of the control group was 84. 85 %（ P < 0. 05）. In the experimental group, local skin itching in the infusion area was seen in 2 patients of experimental group and, 1 in the control group, and insomnia 1 patient. Conclusion Qingfei Huatan Decoction combined with moxifloxacin can shorten the antipyretic time, relieve cough symptoms, and effectively inhibit inflammatory reactions in CAP patients with good clinical efficacy.